Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer

por Scagliotti, G V, Szczesna, A, Ramlau, R, Cardenal, F, Mattson, K, Van Zandwijk, N, Price, A, Lebeau, B, Debus, J, Manegold, C
Publicado 2006

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (...

por Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., Manegold, C.
Publicado 2010

Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lun...

por Camerini, A., Morabito, A., Montanino, A., Bernabé, R., Grossi, F., Ramlau, R., Ciuleanu, T.-E., Ceresoli, G.-L., Pasello, G., de Marinis, F., Bosch-Barrera, J., Laundreau, P., Gautier, S., Ta Thanh Minh, C., Kowalski, D.
Publicado 2021

Epidermal Growth Factor Receptor Mutation Status: Does Younger Mean More Frequently Mutated?

por Wójcik, P, Krawczyk, P, Chorostowska-Wynimko, J, Reszka, K, Duk, K, Muszczyńska-Bernhard, B, Pankowski, J, Wojas-Krawczyk, K, Czyżewicz, G, Ramlau, R, Skoczek, M, Grenda, A, Orłowski, T, Grodzki, T, Piwowar, M, Roszkowski-Śliż, K, Milanowski, J
Publicado 2017

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer

por Tan, E.-H., Ramlau, R., Pluzanska, A., Kuo, H.-P., Reck, M., Milanowski, J., Au, J. S.-K., Felip, E., Yang, P.-C., Damyanov, D., Orlov, S., Akimov, M., Delmar, P., Essioux, L., Hillenbach, C., Klughammer, B., McLoughlin, P., Baselga, J.
Publicado 2010